Natera, Inc. (NASDAQ:NTRA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET

Company Participants

Mike Brophy - CFO
Steve Chapman - CEO
Solomon Moshkevich - President, Clinical Diagnostics
Alexey Aleshin - GM Oncology, CMO

Conference Call Participants

Dan Brennan - Cowen
Rachel Vatnsdal - JP Morgan
Puneet Souda - Leerink Partners
Tejas Savant - Morgan Stanley
Douglas Schenkel - Wolfe Research
Tycho Peterson - Jefferies
Catherine Schulte - Baird
Subbu Nambi - Guggenheim
Eve Burstein - Bernstein

Operator

Good afternoon, and welcome to Natera Inc.'s Q2 Earnings Conference Call. All participants are in a listen-only mode. After the speakers’ remarks, we’ll have a question and answer session. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Mike Brophy, Chief Financial Officer. Thank you. Please go ahead.

Mike Brophy

Thanks, operator. Good afternoon. Thank you for joining our conference call to discuss the results of our second quarter of 2024. On the line, I am joined by Steve Chapman, our CEO; Solomon Moshkevich, President, Clinical Diagnostics; and Alexey Aleshin, General Manager of Oncology and Chief Medical Officer. Today's conference call is being broadcast live via webcast. We will be referring to a slide presentation that has been posted to investor.natera.com. A replay of the call will also be posted to our IR site as soon as it's available.

Starting on Slide 2. During the course of this conference call, we will make forward-looking statements regarding future events and our anticipated future performance, such as our operational and financial outlook and projections, our assumptions for that outlook, market size, partnerships, clinical studies and expected results. Opportunities and strategies and expectations for various current and future products, including product capabilities, expected release dates, reimbursement coverage and related effects on our financial and operating results.

We caution you that such statements reflect our best judgment based on factors currently known to us and that actual events or results could differ materially. Please refer to the documents we file from time to time with the SEC including our most recent Form 10-K or 10-Q and the Form 8-K filed with today's press release. Those documents identify important risks and other factors that may cause our actual results to differ materially from those contained in or suggested by the forward-looking statements. Forward-looking statements made during the call are being made as of today, August 8, 2024.